UBI Group Publications
Rumyantsev A, Wang L, Wang S, Kemp T, Wriggins A, Burks A, Fisher D, Brokke K, Fix A, Hensley S, Lewis M, Zhu R, Shasha C, Piccini G, Manenti A, Montomoli E, DeAntonio R, Saez-Llorens X, Chan M, Alberto E, Borra MDL, Jaen AM, Heppner G, Palm U, Monath TP. “Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.” The Lancet eClinicalMedicine 2025, 86:103349
Rai AM, Blazkova J, Kardava L, Justement JS, Shi V, Manning MR, Shahid A, Dong W, Kennedy BD, Sewack AB, Higgins J, Buckner CM, Gittens K, West RE, Devanthan AS, Mangusan R, Lurain K, Ramaswami R, Yarchoan R, Sneller MC, Pau AK, Brumme ZL, Moir S, Chun TW. “Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.” Nature Medicine 2025, 31:427-432
Rai MA, Blazkova J, Justement JS, Shi V, Kennedy BD, Manning MR, McLaughlin M, Sneller MC, Pau AK, Moir S, Chun TW. “Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.” The Lancet BioMedicine 2024, 104:105151
Eijsvogel P, Misra P, Concha-Marambio L, Boyd JD, Ding S, Fedor L, Hsieh YT, Sun YS, Vroom MM, Farris CM, Ma Y, deKam ML, Radanovic I, Vissers MFJM, Mirski D, Shareghi G, Shahnawaz M, Singer W, Kremer P, Groeneveld GJ, Yu HJ, Dodart JC. “Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.” Nature Medicine 2024, 30:2631-2640
Yu HJ, Dickson SP, Wang PN, Chiu MJ, Huang CC, Chang CC, Liu H, Hendrix SB, Dodart JC, Verma A, Wang CY, Cummings J. “Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer’s disease: a randomized, double-blind, placebo-controlled, phase 2a study.” The Lancet eBioMedicine 2023, 94:104665
Wang S, Guirakhoo F, Periasamy S, Ryan V, Wiggins J, Subramani C, Thibodeaux B, Sahni J, Hellerstein M, Kuzmina N, Bukreyev A, Dodart JC, Rumyantsev A. “RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Response against SARS-CoV-2 in Cynomolgus Macaques.” Vaccines 2023, 12(1),40
Guirakhoo F, Wang S, Wang CY, Kuo HK, Peng WJ, Liu H, Wang L, Johnson M, Hunt A, Hu MM, Monath TP, Rumyantsev, Goldblatt D. “High neutralizing antibody levels against SARS-CoV-2 Omicron BA.1 and BA.2 after UB-612 vaccine booster.” The Journal of Infectious Diseases 2022, 8:1401-1406
Wang S, Wang CY, Kuo HK, Peng WJ, Huang JH, Kuo BS, Lin F, Liu YJ, Liu Z, Wu HT, Ding S, Hou KL, Cheng J, Yang YT, Jiang MH, Wang MS, Chen T, Xia WG, Lin E, Hung CH, Chen HJ, Shih Z, Lin YL, Ryan V, Hu MM, Heppner DG, Malherbe DC, Periasamy S, Kuzmina N, Subramani C, Hellerstein M, Monath TP, Rumyantsev A, Bukreyev A, Guirakhoo F. “A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.” Emerging Microbes & Infections 2022, 11(1):2724-2734
Boyd JD, Wang S, Lin HW, Hsieh YT, Sun YS, Thibodeaux BA, Lu H, Sahni J, Wiggins J, Longo MS, Brooks JK, Vroom MM, Chang YP, Liu Z, Ding S, Dodart JC. “Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide.” Nature Communications Medicine 2025, 5:145
Vroom MM, Lu H, Lewis M, Thibodeaux BA, Brooks JK, Longo MS, Ramos MM, Sahni J, Wiggins J, Boyd JD, Wang S, Ding S, Hellerstein M, Ryan V, Powchik P, Dodart JC. “VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys.” Journal of Lipid Research 2024, 65(2):100497
Yu HJ, Thijssen E, van Brummelen E, van der Plas JL, Radanovic I, Moerland M, Hsieh E, Groeneveld GJ, Dodart JC. “A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.” Movement Disorders 2022, 37:10.1002/mds.29016
Nimmo JT, Smith H, Wang CY, Teeling JL, Nicoll JAR, Verma A, Dodart JC, Liu Z, Lin F, Carare RO. “Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut.” Acta Neuropathologica 2022, 143:55-73
Nimmo JT, Verma A, Dodart JC, Wang CY, Sawistchenko J, Melki R, Carare RO, Nicoll JAR. “Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.” Alzheimer’s Research & Therapy 2020, 12:159
Brown CM, Brooks JK, Kelly L, Vroom MM, Longo M, Dodart JC, Carare R, Boyd JD. “Tau-targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy.” Brain Pathology 2025, e70056
Wang CY, Wang PN, Chiu MJ, Finstad CL, Lin F, Lynn S, Tai YH, Fang XD, Zhao K, Hung CH, Tseng Y, Peng WJ, Wang J, Yu CC, Kuo BS, Frohna PA. “UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer’s disease.” Alzheimer’s & Dementia 2017, 3:262-272
Wang CY, Walfield AM. “Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, and for veterinary applications.” Vaccine 2005, 23:2049-2056.
Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, Fang XD, Hung CH, Birgit H-P and Windisch M. “Site-specific UBITh® amyloid-vaccine for immunotherapy of Alzheimer’s disease.” Vaccine 2007, 25:3041-3052
Hseuh PR, Kao CL, Lee CN, Chen LK, Ho MS, Sia C, Fang XD, Lynn S, et al. “Highly Specific SARS Antibody Test for Serosurveillance.” Emerg. Infect. Diseases 2004, 10:1558-1562
Wang CY, Walfield AM, Fang X, Hammerberg B, Ye J, Li ML, Shen F, Shen M, Alexander V, MacGlashan DW. “Synthetic IgE peptide vaccine for immunotherapy of allergy.” Vaccine 2003, 21: 1580-1590.
Wang CY, Chang TY, Walfield AM, Ye J, Shen M, Chen SP, Li MC, Lin YL, Jong MH, Yang PC, Chyr N, Kramer E, Brown F. “Effective synthetic peptide vaccine for foot-and-mouth disease in swine.” Vaccine 2002, 20:2603-2610
Wang CY, Chang TY, Walfield AM, Ye J, Shen M, Zhang ML, Lubroth J, Chen SP, Li MC, Lin YL, Jong MH, Yang PC, Chyr N, Kramer E, Brown F. “Synthetic peptide-based vaccine and diagnostic system for effective control of FMD.” Biologicals 2001, 29:221-228
Shen F, Chen PD, Walfield AM, Ye J, House J, Brown F, Wang CY. “Differentiation of convalescent animals from those vaccinated against foot-and-mouth disease by a peptide ELISA.” Vaccine 1999, 17:3039-3049
Finstad CL, Wang CY, Kowalski J, Zhang M, Li ML, Li XM, Xia WG, Bosland MC, Murthy KK, Walfield AM, Koff WC, Zamb T. “Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy.” Vaccine 2004, 22: 1300-1313
Ladd A, Walfield AM, Tsong, YY, Thau R. “Active Immunization Against LHRH Alone or Combined With LHRH-Analogue Treatment Impedes Growth of Androgen-Dependent Prostatic Carcinoma.” Am J Reprod Immunol 1995, 34:200-206
Ladd A, Tsong YY, Walfield AM, Thau R. “Development of an antifertility vaccine for pets based on active immunization against luteinizing hormone-releasing hormone.” Biol Repro, 1994, 51:1076-1083
Ladd, A. “Progress in the development of anti-LHRH vaccine.” Am J Repro Immunol 1993, 29:189-194
Kuebler PJ, Nixon DF. “Cytotoxic T cell induction with ratchet peptide libraries.” Vaccine 1996, 14:1664-1670
Geetha P. Bansal. “A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases.” Bethesda, 10 March 2006. Biologicals 2007, 35:367-371
Wang, C.Y. et al. “Synthetic AIDS vaccine by targeting HIV receptor.” Vaccine 2002, 21:89-97
Wang CY, Sawyer LSW, Murthy KK, Fang XD, Walfield AM, et al. “Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex.” Proc. Natl. Acad. Sci. USA 1999, 96:10367-10372
Wang CY, Looney DJ, Li ML, Walfield AM, Ye J, Hosein B, Tam JP & Wong-Staal F. “Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen.” Science 1991, 254:285-288
Koff WC. “The next steps towards a global AIDS vaccine.” Science 1994, 266:1335-1337
Zhang AQ, Geisler SC, Smith AD, Resnick DA, Li ML, Wang CY, et al. “A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1.” Biol Chem 1999, 380:365-374
Li D, Forrest BD, Li Z, Xue P, Hanson CV, Duan S, Cheng H, Li M, Wang CY, et al. “International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.” Asian Pac J Allergy Immunol 1997, 15:105-113
Singh M, McGee JP, Li XM, Koff W, Zamb T, Wang CY, et al. “Biodegradable microparticles with an entrapped branched octameric peptide as a controlled-release HIV-1 vaccine.” J Pharmaceut Sci 1997, 66:1229-1233
Tsuji T, Hamajima K, Fukushima J, Xin KQ, Koff WC, et al. “Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12.” J Immunol 1997, 158:4008-4013
Okuda K, Xin KO, Tsuji T, Bukawa H, Tanaka S, Koff WC, et al. “DNA vaccination followed by macromolecular- multicomponent peptide vaccination against HIV-1 induces antigen-specific immunity.” Vaccine 1997, 15:1049-1056
Phanuphak P, Teeratakulpixarn S, Sarangbin S, Nookhai S, Ubolyam S, Sirivichayakul S, Leesavan A, Forrest BD, Hanson CV, Li ML, Wang CY, et al. “International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand.” Asian Pac J Allerg Immunol 1997, 15:41-48
Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, et al. “A dose-ranging study of a prototype synthetic HIV-1 MN V3 branched peptide vaccine.” J Infect Dis 1996, 173:330-339
Koff WC, Schultz AM. “Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm.” J Clin Immunol 1996, 16:127-133
Richardson JJ, McGee JP, Gumear D, Potts B, et al. “Controlled release antigen delivery systems for mucosal immunization with a HIV-1 peptide in small animal models.” Proceed Intern Symp Control Rel Bioact Mater 1994, 21
Walfield AM, Li ML, Looney DJ, Hosein B, Wong-Staal F & Wang CY. “High-titer neutralization of multiple HIV-1 isolates by radially branched immunogens.” In: Koff WC et al. eds. AIDS Research Reviews Vol. 3. New York: Marcel Dekker, Inc. 1993, 345-360
Looney DJ, Li M, Walfield A, Hosein B, Badel P, Wang CY & Wong-Staal F. “Type-specific and cross-reactive neutralizing antisera against HIV elicited by V3-peptide heptalysine octomers.” AIDS Res Hum Retroviruses 1992, 8:1381
Walfield AM, Li ML, Ye J, Hosein B, Fang XD, Wang CY, Looney DJ & Wong-Staal F. “Induction of high-titer persistent neutralizing antibodies by HIV-1 V3 octa-branched peptides.” Vaccines 92: Modern Approaches to New Vaccines Including Prevention of AIDS, Chanock RM et al (ed), Cold Spring Harbor Laboratory Press 1992, 211-215
Wang JG, Steel S, Wisniewolski R & Wang CY. “Detection of antibodies to HTLV-III using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein.” Proc Natl Acad Sci USA 1986, 83: 6159-6163
Khabbaz RF, Onorato IM, Cannon RO, Hartley TM, Hosein B, et al. “Seroprevalence of HTLV-I and HTLV-II among intravenous drug users and persons in clinics for sexually transmitted diseases.” N Eng J Med 1992, 326:375-380
Wang CY. “Synthetic-peptide-based immunodiagnosis of retrovirus infection: current status and future prospects. In “Synthetic Peptides in Biotechnology.” Edited by A. Mizrahi, Adv. in Biotechnological Processes 1988, 10:131-148
Gonzalez L, Boyle RW, Zhang M, Castillo J, Whittier S, Della-Latta P, Clarke LM, George JR, Fang XD, Wang JG, Hosein B, Wang CY. “Synthetic-peptide-based enzyme-linked immunosorbent assay for screening human serum or plasma for antibodies to HIV-1 and 2.” Clin Diag Lab Immunol 1997, 4:598-603
Maytel J, Horowitz S, L ipper S, Poiesz B, Wang CY & Siegal FP. “Progressive nemaline rod myopathy in a woman coinfected with HIV-1 and HTLV-2.” Mt Sinai J Med 1993, 60:242
Hosein B, Present W, Wang CY & Fang CT. “Synthetic peptide-based EIAs to distinguish HTLV-I from HTLV-II infection.” Transfusion 1990, 30S:513.
Coulis PA, Wang JJG, Kang EP, Present W & Wang CY. “Peptide-based immunodiagnosis of retrovirus infection.” Am Clin Prod Rev. Nov. 1987
Hosein B, Fang CT, Popvsky MA, Ye J, Zhang M & Wang CY. “Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein.” Proc Natl Acad Sci USA 1991, 88:3647-3651
Hosein B, Fang X & Wang CY. “Anti-HCV, anti-GOR, and autoimmunity.” Lancet 1992, 339: 871
Prince AM, Brotman B, Inchauspe G, Pascual D, Nasoff M, Hosein B & Wang CY. “Patterns and prevalence of hepatitis type C infection in post-transfusion non-A, non-B hepatitis.” J Inf Dis 1993, 167:1296-1301
Quiroga JA, van Binsbergen J, Wang CY, Pardo M, Navas S, Trines C, Herrero M & Carreno V. “Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with viral replication, histological activity, and liver disease outcome.” Hepatol 1995, 22:1635-1640
DeVault KR, Friedman LS, Westerberg S, Hosein B, et al. “Hepatitis C in sickle cell anemia.” J Clin Gastroenterol 1994, 18:206-209
Silva AE, Hosein B, Boyle RW, Fang CT, Shindo M, et al. “Diagnosis of chronic hepatitis C: comparison of immunoassays and the polymerase chain reaction.” Am J Gastroenterol 1994, 89:493-496
Sheu JC, Wang JT, Wang TH, Wang CY, et al. “Prevalence of hepatitis C viral infection in a community in Taiwan. Detection by synthetic peptide-based assay and polymerase chain reaction.” J Hepatol 1993, 17:192-198
Wang JT, Wang TH, Sheu JC, Tsai SJ, Hsieh YS, Lin DT, Wang CY & Chen DS. “Hepatitis C virus infection in volunteer blood donors in Taiwan. Evaluation by hepatitis C antibody assays and the polymerase chain reaction.” Arch Pathol Lab Med 1993, 117:152-156
Sheu JC, Huang GT, Shih LN, Lee WC, Chou HC, Wang JT, Lee PH, Lai MY, Wang CY, Yang PM, et al. “Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma.” Gastroenterology 1992, 103:1322-1327
Wang JT, Wang TH, Sheu JC, Lin JT, Wang CY & Chen DS. “Posttransfusion hepatitis revisited by hepatitis C antibody assays and polymerase chain reaction.” Gastroenterology 1992, 103: 609-616
Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, and O’Hagan DT. “Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models.” Vaccine 1998, 16:346-352
Singh M, Hioe C, Qiu H, Li XM, Wang CY, Koff W, Zamb T, and Nixon DF. “CTL induction using synthetic peptides delivered in emulsions – critical role of the formulation procedure.” Vaccine 1997, 15:1773-1778
Singh M, Li XM, McGee JP, Zamb T, Koff W, Wang CY, and O’Hagan DT. “Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immnogenicity in mice.” Vaccine 1997, 15:475-481
Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, and O’Hagan DT. “Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine.” Infect Immun 1997, 65:1716-1721
McGee JP, Singh M, Li XM, Qiu H, O’Hagan DT. “The encapsulation of a model protein in poly (D,L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility.” J Microencapsul 1997, 14:197-210
Hioe CE, Qiu H, Chen PD, Bian Z, Li ML, Li J, Singh M, Kuebler P, McGee P, O’Hagan D, Zamb T, Koff W, Allsopp C, Wang CY, and Nixon DF. “Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides.” Vaccine 1996, 14:412-418
Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY & O’Hagan D. “Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity.” Vaccine 1996, 14:1523-1530
O’Hagan DT. “Microparticles as oral vaccines. In Novel Delivery Systems for Oral Vaccines,” O’Hagan ed., CRC Press, pp 175-205, 1994
Shimazaki C, Wisniewolski D, Scheinberg D, Atzpodien J, Strife A, Gulati S, Fried J, Wismienolski R, Wang CY & Clarkson B. “Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads.” Blood 1988, 72:1248
Rinnooy-Kan EA, Wright SD, Welte K & Wang CY. “Fc receptors on monocytes cause OKT-3 treated lymphocytes to internalize T3 and secrete IL-2.” Cell Immunol 1986, 98: 181
Fried J, Shimazaki C, Perez AC, Wisniewolski R & Wang CY. “Application of flow cytometry to the analysis of multiple myeloma cells and their progenitors.” Flow Cytometry Boca Roton, Fl. CRC. 1986
Wang CY, Bushkin Y, Pica R, Lane CL, McGrath H & Posnett DN. “Stimulation and expansion of a human T cell subpopulation by a monoclonal antibody to T cell receptor molecule.” Hybridoma 1986, 5:179
Posnett DN, Folkl RJ & Wang CY. “A hairy cell leukemia-associated antigen (HC2) has a distinct role in normal B cell differentiation.” Leukemia 1987, 1:3832
Posnett D, Wang CY & Friedman SM. “Inherited polymorphism of the human T cell antigen receptor detected by a monoclonal antibody.” Proc Natl Acad Sci USA 1986, 83:7888-7892
Tse DB, Al-Haiden M, Pernis B, Cantor CR & Wang CY. “Intracellular accumulation of T cell receptor complex molecules in a human T leukemia cell line.” Science 1986, 234:748
Al-Katib A, Wang CY & Koziner B. “Distribution of a new B cell associated surface antigen (BL7) detected by a monoclonal antibody in human leukemic disorders.” Cancer Research 1985, 45:3058
Schwarting R, Stein H & Wang CY. “Monoclonal antibodies S-HCL1 and S-HCL3 allow the diagnosis of hairy cell leukemia.” Blood 1985; 65: 974
Schwarting R, Welte K, Chiorazzi N, Ralph P, Lane CL, Long CW, & Wang CY. “Biochemical characterization and purification of human B cell stimulatory factor (BSF).” Eur J Immunol 1985, 15:632
Al-Katib A, Wang CY, McKenzie S, Clarkson BD & Koziner B. “Phorbol ester-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.” Am J Hematology 1992, 40: 264
Kao HT, Gregerson PK, Tang JC, Takahashi T, Wang CY & Silver J. “Molecular analysis of HLA class genes in two DR6w-related haplotypes, DRw13 DQw1 and DRw14 DQw3.” J Immunol 1989, 142: 1743
Takahashi TC, Kao HT, Tang JC, Gregerson PK, Silver J & Wang C Y. “Molecular diversity of HLA-DRw6 haplotypes.” Immunobiology of HLA 1988 2:218
Sung SSJ, Bjorndahl JM, Wang CY, Kao HT & Fu SM. “Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by PMA and anti-CD3 antibody.” J Exp Med 1988, 167: 937-953
Sung SSJ, Jung LKL, Walters JA, Chen W, Wang CY & Fu SM. “Production of tumor necrosis factor/cachetin by human B cell lines and tonsillar B cells.” J Exp Med 1988, 168:1539-1551
Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY & Carter DM. “Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques.” J Exp Med 1986, 164: 1013-1028
Gregerson P, Shen M, Song Q, Wang CY, et al. “Molecular diversity of HLA-DR4 haplotypes.” Proc Natl Acad Sci USA 1986, 83: 2642-2646
Buskin Y, Posnett DN, Pernis B & Wang CY. “A new HLA-linked T cell membrane molecule, related to the beta chain of the clonotypic receptor, is associated with T3.” J Exp Med 1986, 164:458-473
Bushkin Y, Chorney MJ, Diamante E, Lane CL, Fu SM & Wang CY. “Biochemical characterization of a p43,12 complex: comparison to human and murine class I molecules.” Mol Immunol 1985, 22:695.
Knowles DM, Dodson L, Burke JS, Wang M, Bonetti F, Pelicci P, Flug F, Dalla-Favera R & Wang CY. “SIg- (“Null-cell”) non-Hodgkin’s lymphomas: multiparametric determination of their B- or T-cell lineage.” Am J Path 1985, 120:356
Flug F, Dodson L, Wang CY, Wolff JA, Rausen A, Guarini L, & Knowles DM. “B lymphocyte associated differentiation antigen expression by “non-B, non-T” acute lymphoblastic leukemia.” Leu Res 1985, 9:1051
Buskin Y, Kunkel HG, Pernis B & Wang CY. “Evidence for a second receptor-like molecule in a human T cell leukemia.” In: “Cell Biology of the Major Histocompatibility Complex.” Edited by B. Pernis, and H.J. Vogel, New York, Academic Press. 1985; pp173-183.